top of page

FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy

Writer: nuaxia
nuaxia
1 hour ago
2 min read

The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.


Roche announced on 16 November 2026 that the US Food and Drug Administration had approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy who are at risk of disease progression, providing the first medicine specifically authorised to induce remission of proteinuria in this autoimmune kidney disorder.


In the Phase III MAJESTY trial, approximately 36% of patients receiving Gazyva achieved complete proteinuria remission at week 104 compared with approximately 6% receiving tacrolimus, while the medicine's existing boxed warnings include hepatitis B reactivation and progressive multifocal leukoencephalopathy; this is a new indication for an already authorised medicine rather than obinutuzumab's first FDA approval.

Field

Content

Article Type

Approvals

Company

Roche

Product Brand Name

Gazyva

Active Ingredient

Obinutuzumab

Drug Classification

Anti-CD20 monoclonal antibody

Regulatory Authority

US Food and Drug Administration

Announcement Date

16 November 2026

Regulatory Decision

New indication approval

Geographic Scope

United States

Therapeutic Area

Nephrology

Disease

Primary membranous nephropathy

Disease Classification

Autoimmune kidney disorder

Approved Population

Adults with primary membranous nephropathy at risk of disease progression

Treatment Objective

Induction of proteinuria remission

First FDA-Approved Treatment for Condition

Yes

Existing Product

Gazyva was previously approved for other indications

Supporting Clinical Trial

MAJESTY

Clinical Trial Phase

Phase III

Key Efficacy Measure

Complete proteinuria remission

Assessment Time Point

Week 104

Gazyva Complete Remission Rate

Approximately 36%

Comparator

Tacrolimus

Comparator Complete Remission Rate

Approximately 6%

Approximate Absolute Remission Difference

30 percentage points

Boxed Warning One

Hepatitis B virus reactivation

Boxed Warning Two

Progressive multifocal leukoencephalopathy

What Happened

The FDA approved obinutuzumab for adults with primary membranous nephropathy at risk of progression.

Why It Matters

The decision establishes the first specifically authorised pharmacological treatment for a condition previously managed without an FDA-approved disease-specific medicine.

Clinical Significance

The MAJESTY study demonstrated higher complete proteinuria remission rates with Gazyva than with tacrolimus at week 104.

Regulatory Significance

Expands an existing medicine into a new nephrology indication.

Safety Significance

The treatment carries serious infection-related boxed warnings requiring appropriate clinical precautions.

Key Takeaway

Gazyva is now the first FDA-approved medicine specifically for primary membranous nephropathy.

What to Watch

Treatment uptake, nephrology guidelines, reimbursement, long-term kidney outcomes and real-world safety.

Primary Source

US Food and Drug Administration

Primary Source URL

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy

Submitted Source

GeneOnline

Submitted Source URL

https://www.geneonline.com/gazyva-becomes-first-fda-approved-treatment-for-primary-membranous-nephropathy-after-years-of-off-label-care/

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page